Among the long-acting injectable antipsychotics, olanzapine pamoate — sold as Zyprexa Relprevv — is the unusual one. It delivers olanzapine, one of the most effective antipsychotics ever studied, in an injection that lasts two to four weeks. It also carries a risk that no other LAI on the US market shares: post-injection delirium / sedation syndrome (PDSS). That single side effect has shaped how the medication is used, where it can be administered, and why many patients and clinicians choose alternatives despite the drug's strong efficacy.
Zyprexa Relprevv is the long-acting injectable form of olanzapine, FDA-approved for schizophrenia, with a small but real risk of post-injection delirium / sedation syndrome that requires three hours of in-clinic observation after every dose.
What it is
Olanzapine pamoate is olanzapine bound to pamoic acid in a microcrystalline suspension. After deep gluteal intramuscular injection, the crystals dissolve slowly, releasing olanzapine into circulation over weeks. It was approved by the FDA in 2009 for the treatment of schizophrenia in adults who had been previously stabilised on oral olanzapine.
The post-injection syndrome — what actually happens
If a small portion of the depot is accidentally injected into a blood vessel rather than into muscle tissue, an unusually large dose of olanzapine can be released rapidly. Within minutes to a few hours, the patient may develop:
- Profound sedation, sometimes to the point of unresponsiveness
- Confusion or delirium
- Slurred speech, ataxia, dizziness
- Cardiovascular changes — usually transient
- Less often, seizure
Symptoms typically resolve within 24 to 72 hours. Most cases require supportive care only; serious harm is rare but possible. The estimated incidence is approximately 0.07% per injection, or about 1 to 2 events per 1,000 injections, based on the manufacturer's pooled safety data and FDA review.
Why three hours of monitoring
Because PDSS can begin within minutes but symptoms occasionally take an hour or more to appear, the FDA requires that every patient receiving Zyprexa Relprevv be observed for at least three hours after each injection at a healthcare facility with an alert observer present. This requirement is enforced through a Risk Evaluation and Mitigation Strategy (REMS) program — the Zyprexa Relprevv Patient Care Program — which certifies prescribers, healthcare facilities, and pharmacies.
During the observation period, the patient is monitored for sedation, dizziness, confusion, and other PDSS signs. If symptoms appear, the patient is managed in the facility or transferred to a higher level of care. The patient cannot drive home; transportation must be arranged.
Practical implications
Three hours of in-clinic observation after every injection has significant implications for patients and families:
- Half a workday lost every two to four weeks
- Need for a clinic equipped to observe (chairs, staff, monitoring)
- Transportation arrangements required
- Logistical burden particularly high in rural settings
For these reasons, Zyprexa Relprevv is the least commonly used LAI in many US settings. It is most often chosen when oral olanzapine has worked well and other LAIs have not, or when the metabolic and clinical profile of olanzapine is specifically what the patient needs.
Dosing
Per FDA labelling, target maintenance doses depend on the previous oral olanzapine dose. Common regimens include:
- 10 mg/day oral olanzapine → 210 mg every 2 weeks (first 8 weeks), then 150 mg every 2 weeks or 300 mg every 4 weeks
- 15 mg/day oral → 300 mg every 2 weeks initially, then 210 mg every 2 weeks or 405 mg every 4 weeks
- 20 mg/day oral → 300 mg every 2 weeks throughout
Specifics are individualised. Unlike many other LAIs, oral overlap is generally not required, because olanzapine pamoate produces useful blood levels within days.
Other side effects
Beyond PDSS, the side effect profile largely mirrors oral olanzapine:
- Weight gain — often substantial; see our olanzapine weight gain guide
- Metabolic effects — diabetes risk, lipid changes, insulin resistance
- Sedation — common
- Increased appetite
- Injection-site reactions — pain, swelling, induration
During the three-hour observation period (or after going home), you experience profound drowsiness, confusion, slurred speech, or trouble walking. PDSS is usually self-limited but requires medical assessment.
Where it fits today
Zyprexa Relprevv is rarely a first-line LAI. It is most appropriate when:
- The patient has had a clear, durable response to oral olanzapine
- Other LAIs have been tried and didn't work
- A clinic equipped for the three-hour observation is accessible
- The patient and family understand and accept the PDSS risk
For many patients who would benefit from olanzapine's efficacy, prescribers instead use oral olanzapine with adherence supports, or pair it with an LAI of a different antipsychotic.
What to ask before starting
- What is the actual evidence that I need this specific LAI rather than another?
- How will the three-hour observation work logistically — every two weeks or every four?
- What's the plan for transportation home?
- How will we manage weight and metabolic changes long-term?
- If I develop PDSS, what happens — and will I be re-injected next time?
This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed sources. Always consult your prescribing clinician before starting, stopping, or changing any medication.